Form 4: Roivant Director Sells $38M in Shares

Roivant Sciences Director and 10% owner Vivek Ramaswamy sold over 1.8 million common shares for approximately $38 million in mid-November 2025.

Summary

• Vivek Ramaswamy, a Director and 10% owner of Roivant Sciences Ltd. (ROIV), reported sales of common shares.
• On November 13, 2025, 287,283 common shares were sold at a weighted average price of $20.81 per share, with prices ranging from $20.54 to $21.08.
• On November 14, 2025, 1,027,670 common shares were sold at a weighted average price of $20.33 per share, with prices ranging from $20.00 to $21.11.
• On November 17, 2025, 539,650 common shares were sold at a weighted average price of $20.51 per share, with prices ranging from $20.20 to $20.72.
• The total number of shares sold across these three transactions is 1,854,603, amounting to approximately $37.94 million.
• Following these transactions, Vivek Ramaswamy directly beneficially owns 33,653,756 common shares.
• An additional 13,357,857 common shares are held indirectly through a spousal relationship.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 3

Explanation: The significant sale of shares by a director and 10% owner, Vivek Ramaswamy, indicates a potentially negative sentiment from a key insider, despite the sales being executed at relatively high prices and under a 10b5-1 plan. This could signal a strategic reduction in exposure.

Negatives

• Significant insider selling by a director and 10% owner, Vivek Ramaswamy, totaling over 1.8 million shares for approximately $38 million.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Vivek Ramaswamy, a Director and 10% owner, engaged in direct sales of common shares. Additionally, 13,357,857 common shares are held indirectly through a spousal relationship.

Stakeholder Impact

• Shareholders may perceive the significant insider selling by a director and 10% owner as a negative signal regarding the company's future prospects, potentially leading to downward pressure on the stock price. However, the sales were conducted under a Rule 10b5-1 plan, which suggests pre-scheduled transactions rather than a reaction to immediate company news.

Key Dates

Recommendation

The substantial sale of over 1.8 million shares by Vivek Ramaswamy, a Director and 10% owner, for approximately $38 million, is a significant event. While these transactions were executed under a Rule 10b5-1 plan, indicating they were pre-scheduled and not necessarily a reaction to immediate company developments, they still represent a key insider reducing their stake. The sales occurred at prices ranging from $20.00 to $21.11, which could be considered a favorable exit point. Investors should monitor future insider activity and company performance closely. Without additional context on the company's fundamentals or the specific motivations beyond diversification or liquidity, a 'hold' recommendation is prudent, suggesting investors maintain their current positions while awaiting further clarity.

Keywords

Roivant Sciences, ROIV, Vivek Ramaswamy, Insider Selling, Form 4, Share Sale, Director Transaction, 10% Owner, 10b5-1 Plan